MA33229B1 - Immunoconjugues anti-mesotheline et leurs utilisations - Google Patents

Immunoconjugues anti-mesotheline et leurs utilisations

Info

Publication number
MA33229B1
MA33229B1 MA34308A MA34308A MA33229B1 MA 33229 B1 MA33229 B1 MA 33229B1 MA 34308 A MA34308 A MA 34308A MA 34308 A MA34308 A MA 34308A MA 33229 B1 MA33229 B1 MA 33229B1
Authority
MA
Morocco
Prior art keywords
antibodies
immunoconjugates
mesothelin
tumors
agents
Prior art date
Application number
MA34308A
Other languages
English (en)
Inventor
Antje Kahnert
Kerstin Berhoerster
Iring Heisler
Charlotte Christine Kopitz
Joachim Schumacher
Original Assignee
Bayer Pharma AG
Cabinet Ghars
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Cabinet Ghars filed Critical Bayer Pharma AG
Publication of MA33229B1 publication Critical patent/MA33229B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur des immunoconjugués composés d'anticorps, par exemple d'anticorps monoclonaux ou de fragments d'anticorps qui se lient à la mésothéline, qui sont conjugués à des agents cytotoxiques, par exemple, la maytansine ou des dérivés de celle-ci, et/ou co-administrés ou formulés avec un ou plusieurs agents anti-cancéreux supplémentaires. Les immunoconjugués de l'invention peuvent être utilisés dans les procédés de l'invention pour traiter et/ou diagnostiquer et/ou surveiller des cancers, par exemple des tumeurs solides. Les immunoconjugués comprennent des anticorps et des fragments fonctionnels contenant de telles régions de liaison à l'antigène qui sont spécifiques pour le polypeptide de mésothéline de 40 kDa ancré à la membrane qui est surexprimé dans plusieurs tumeurs, telles que des tumeurs pancréatiques et ovariennes, des mésothéliomes et des cellules du cancer du poumon.
MA34308A 2009-04-29 2010-04-16 Immunoconjugues anti-mesotheline et leurs utilisations MA33229B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09005909 2009-04-29
PCT/EP2010/002342 WO2010124797A1 (fr) 2009-04-29 2010-04-16 Immunoconjugués anti-mésothéline et leurs utilisations

Publications (1)

Publication Number Publication Date
MA33229B1 true MA33229B1 (fr) 2012-04-02

Family

ID=42332769

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34308A MA33229B1 (fr) 2009-04-29 2010-04-16 Immunoconjugues anti-mesotheline et leurs utilisations

Country Status (42)

Country Link
US (5) US9084829B2 (fr)
EP (2) EP2424569B1 (fr)
JP (3) JP5616433B2 (fr)
KR (1) KR101681795B1 (fr)
CN (2) CN106177984B (fr)
AR (1) AR076284A1 (fr)
AU (1) AU2010243942B2 (fr)
BR (1) BRPI1014637B1 (fr)
CA (1) CA2760114C (fr)
CL (1) CL2011002681A1 (fr)
CO (1) CO6450601A2 (fr)
CR (1) CR20110566A (fr)
CU (1) CU23929B1 (fr)
CY (2) CY1119738T1 (fr)
DK (2) DK2424569T3 (fr)
DO (1) DOP2011000331A (fr)
EC (1) ECSP11011423A (fr)
ES (2) ES2790732T3 (fr)
GT (1) GT201100269A (fr)
HK (1) HK1170671A1 (fr)
HN (1) HN2011002834A (fr)
HR (2) HRP20180015T1 (fr)
HU (2) HUE049795T2 (fr)
IL (1) IL215769A (fr)
JO (1) JO3486B1 (fr)
LT (2) LT2424569T (fr)
MA (1) MA33229B1 (fr)
MX (1) MX2011011365A (fr)
MY (1) MY158624A (fr)
NO (1) NO2424569T3 (fr)
NZ (1) NZ596013A (fr)
PE (1) PE20120556A1 (fr)
PL (2) PL2424569T3 (fr)
PT (2) PT2424569T (fr)
SG (1) SG175254A1 (fr)
SI (2) SI3292874T1 (fr)
TN (1) TN2011000547A1 (fr)
TW (2) TW201529084A (fr)
UA (2) UA106492C2 (fr)
UY (1) UY32560A (fr)
WO (1) WO2010124797A1 (fr)
ZA (1) ZA201107757B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32560A (es) * 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
AU2011349443B2 (en) 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
KR20220009505A (ko) 2011-03-29 2022-01-24 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
WO2012135517A2 (fr) 2011-03-29 2012-10-04 Immunogen, Inc. Préparation de conjugués de maytansinoïde anticorps par procédé en une étape
WO2014004549A2 (fr) * 2012-06-27 2014-01-03 Amgen Inc. Protéines de liaison anti-mésothéline
EP2888282B1 (fr) 2012-08-21 2018-03-14 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anticorps monoclonaux spécifiques au domaine de la mésothéline et utilisation de ces derniers
WO2014043523A1 (fr) * 2012-09-14 2014-03-20 The Johns Hopkins University Compositions et procédés pour rendre des cellules tumorales sensibles à la destruction à médiation par des lymphocytes t cd8+
CA2885761C (fr) * 2012-09-27 2021-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps diriges contre la mesotheline et procedes d'induction d'une activite anticancereuse puissante
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
TR201909034T4 (tr) * 2013-10-25 2019-07-22 Bayer Pharma AG Yeni bir stabil formülasyon.
TWI541022B (zh) * 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
WO2015200773A1 (fr) * 2014-06-27 2015-12-30 Oregon Health & Science University Composés se liant au dystroglycane et utilisations de ceux-ci
EP3193828B8 (fr) * 2014-08-29 2023-04-05 Corium Pharma Solutions, Inc. Réseaux à microstructures pour l'administration d'agents actifs
KR20170088905A (ko) 2014-11-19 2017-08-02 이뮤노젠 아이엔씨 세포 결합 작용제-세포독성 작용제 접합체를 제조하기 위한 공정
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
CA2996060A1 (fr) * 2015-08-21 2017-03-02 Carsgen Therapeutics, Ltd Anticorps entierement humains anti-mesotheline et cellules effectrices immunitaires ciblant la mesotheline
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
SG11201806478PA (en) 2016-02-05 2018-08-30 Immunogen Inc Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
WO2018048975A1 (fr) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Utilisation d'un anticorps anti-pd-1 en combinaison avec un anticorps anti-mésothéline dans le traitement du cancer
KR101966362B1 (ko) * 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
WO2019105835A1 (fr) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinaisons de copanlisib et d'anetumab ravtansine
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
US20210340272A1 (en) * 2018-06-18 2021-11-04 Anwita Biosciences, Inc. Anti-mesothelin constructs and uses thereof
CN112512587A (zh) 2018-08-06 2021-03-16 第一三共株式会社 抗体药物缀合物和微管蛋白抑制剂的组合
WO2020234114A1 (fr) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Nouvelle formulation stable à haute concentration pour anetumab ravtansine
CN111793131A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中pf4含量的抗体对及其用途
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
CA3191387A1 (fr) 2020-09-30 2022-04-07 Nobell Foods, Inc. Proteines de lait recombinantes et compositions les comprenant
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
KR20230135107A (ko) 2021-01-22 2023-09-22 바이엘 악티엔게젤샤프트 Lrrc15 항체 및 그의 접합체
KR20230121560A (ko) 2022-02-10 2023-08-18 경북대학교 산학협력단 메소세린에 결합하는 펩타이드 및 이의 용도

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1437180A (en) 1920-12-16 1922-11-28 Wahl Co Mechanical pencil
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (fr) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotique C-15003 PHO et sa préparation
WO1982001188A1 (fr) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
WO1992005793A1 (fr) 1990-10-05 1992-04-16 Medarex, Inc. Immunostimulation ciblee induite par des reactifs bispecifiques
EP0557300B1 (fr) 1990-10-29 1997-11-19 Chiron Corporation Anticorps bispecifiques, methodes de production et utilisation desdits anticorps
US5773280A (en) 1992-03-20 1998-06-30 The Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
AU665758B2 (en) 1991-04-26 1996-01-18 Surface Active Limited Novel antibodies, and methods for their use
US5407653A (en) 1991-06-26 1995-04-18 Brigham And Women's Hospital Evaluation of the multidrug resistance phenotype
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
JPH0699141A (ja) * 1992-09-21 1994-04-12 Kubota Corp 石抜装置
JPH06124641A (ja) * 1992-10-08 1994-05-06 Mitsubishi Electric Corp 回路遮断器
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1996013583A2 (fr) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Hetero-association ciblee de proteines recombinees et de complexes fonctionnels
JPH0945957A (ja) * 1995-07-28 1997-02-14 Oki Electric Ind Co Ltd 端面発光型ｌｅｄアレイの製造方法及びその検査方法
JP3724015B2 (ja) * 1995-08-08 2005-12-07 コベルコ建機株式会社 パイロット切換弁の応答性可変装置
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
US7375183B1 (en) * 1996-01-05 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof
EP0871492B1 (fr) 1996-01-05 2003-11-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Antigene de mesothelium, procedes et kits de ciblage de celui-ci
EP1005569A2 (fr) 1997-08-01 2000-06-07 MorphoSys AG Nouvelle methode et nouveau phage d'identification d'une sequence d'acide nucleique
EP1030839B1 (fr) 1997-11-10 2004-02-04 G.D. SEARLE & CO. Emploi d'iminosucres alkyles pour traiter la resistance multiple aux anticancereux
DE69833459T2 (de) * 1997-12-01 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung
US6809184B1 (en) 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
CA2369433A1 (fr) 1999-02-26 2000-08-31 Pacific Northwest Research Institute Techniques et compositions pour le diagnostic de carcinomes
DE60044997D1 (de) 1999-07-02 2010-11-04 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
IL142025A0 (en) 1999-07-20 2002-03-10 Morphosys Ag Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1233752B1 (fr) 1999-11-30 2005-01-26 The Arizona Board of Regents on behalf of The University of Arizona Liposomes radiosensibles
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
NZ537610A (en) 2002-07-02 2006-07-28 Smithkline Beecham Corp Stable formulations of the C242 antibody
BRPI0410260A (pt) 2003-05-14 2006-05-16 Immunogen Inc composição conjugada para medicamento
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
EP1659918B1 (fr) 2003-08-08 2009-01-14 Amgen Fremont Inc. Anticorps diriges vers l'hormone parathyroide et leurs utilisations
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
CN1993146A (zh) * 2004-06-01 2007-07-04 健泰科生物技术公司 抗体－药物偶联物和方法
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
ES2503719T3 (es) * 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
WO2006099141A2 (fr) * 2005-03-10 2006-09-21 Morphotek, Inc. Anticorps diriges contre la mesotheline
US20090047211A1 (en) * 2005-05-12 2009-02-19 The Govt. Of The U.S. As Represented By The Sec. Of The Dept. Of Health And Human Services Anti-mesothelin antibodies useful for immunological assays
PT3620171T (pt) 2005-05-18 2022-06-30 Morphosys Ag Anticorpos anti-gm-csf e suas utilizações
AU2006252733A1 (en) 2005-06-02 2006-12-07 Astrazeneca Ab Antibodies directed to CD20 and uses thereof
ZA200800907B (en) * 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
JP2009503105A (ja) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
US20090306101A1 (en) * 2005-11-11 2009-12-10 Flavio Solca Combination treatment of cancer comprising egfr/her2 inhibitors
WO2007062040A1 (fr) 2005-11-22 2007-05-31 Wyeth Preparations a base de proteines hybrides d'immunoglobuline
EP1854478A1 (fr) 2006-05-12 2007-11-14 Cytos Biotechnology AG Composition vaccinale comprenant des conjugués nicotine-porteur
US8128926B2 (en) * 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
PL2195017T3 (pl) * 2007-10-01 2015-03-31 Bristol Myers Squibb Co Ludzkie antyciała, które wiążą mezotelinę i ich zastosowania
US9023351B2 (en) 2007-11-26 2015-05-05 Bayer Intellectual Property Gmbh Anti-mesothelin antibodies and uses thereof
KR20210100223A (ko) * 2008-04-30 2021-08-13 이뮤노젠 아이엔씨 가교제 및 그 용도
US20090298088A1 (en) * 2008-05-30 2009-12-03 Belyaev Alexander S Cleavable catalytic binding and detection system
JP2011524421A (ja) * 2008-06-16 2011-09-01 イミュノジェン・インコーポレーテッド 新規の相乗効果
JP5815403B2 (ja) * 2008-08-05 2015-11-17 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法
CN102413839A (zh) 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
EP2411416A1 (fr) * 2009-03-24 2012-02-01 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Anticorps anti-mésothéline
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
LT2437790T (lt) * 2009-06-03 2019-06-10 Immunogen, Inc. Konjugavimo būdai
EP2699268A2 (fr) 2011-04-21 2014-02-26 Seattle Genetics, Inc. Nouveaux conjugués liant-principe actif (adc) et leur utilisation
TR201909034T4 (tr) 2013-10-25 2019-07-22 Bayer Pharma AG Yeni bir stabil formülasyon.

Also Published As

Publication number Publication date
WO2010124797A8 (fr) 2011-12-08
ES2790732T3 (es) 2020-10-29
EP3292874A1 (fr) 2018-03-14
CU20110200A7 (es) 2012-06-21
MY158624A (en) 2016-10-31
TWI472343B (zh) 2015-02-11
JP5616433B2 (ja) 2014-10-29
NZ596013A (en) 2013-11-29
AR076284A1 (es) 2011-06-01
LT3292874T (lt) 2020-06-10
IL215769A0 (en) 2012-01-31
JP2015042174A (ja) 2015-03-05
ES2655273T3 (es) 2018-02-19
PT2424569T (pt) 2018-01-11
CR20110566A (es) 2012-02-20
TN2011000547A1 (en) 2013-05-24
UA116874C2 (uk) 2018-05-25
KR20120031265A (ko) 2012-04-02
HRP20180015T1 (hr) 2018-02-09
CU23929B1 (es) 2013-07-31
US20180201690A1 (en) 2018-07-19
JP2012525342A (ja) 2012-10-22
US20200377614A1 (en) 2020-12-03
WO2010124797A1 (fr) 2010-11-04
CY1123165T1 (el) 2021-10-29
CN106177984B (zh) 2019-12-24
RU2011148220A (ru) 2013-06-10
JP6395783B2 (ja) 2018-09-26
CL2011002681A1 (es) 2012-07-13
EP2424569B1 (fr) 2017-10-18
ECSP11011423A (es) 2011-11-30
DK3292874T3 (da) 2020-06-02
US10781263B2 (en) 2020-09-22
TW201105351A (en) 2011-02-16
JO3486B1 (ar) 2020-07-05
CN106177984A (zh) 2016-12-07
DK2424569T3 (en) 2018-01-15
TW201529084A (zh) 2015-08-01
CN102458477A (zh) 2012-05-16
EP2424569A1 (fr) 2012-03-07
US20150322160A1 (en) 2015-11-12
CA2760114C (fr) 2017-11-21
DOP2011000331A (es) 2011-11-15
PL3292874T3 (pl) 2020-10-19
US20170327589A1 (en) 2017-11-16
GT201100269A (es) 2013-08-21
US10647779B2 (en) 2020-05-12
ZA201107757B (en) 2012-12-27
AU2010243942A1 (en) 2011-11-10
SI3292874T1 (sl) 2020-07-31
SG175254A1 (en) 2011-11-28
HUE049795T2 (hu) 2020-10-28
IL215769A (en) 2016-12-29
KR101681795B1 (ko) 2016-12-01
UA106492C2 (uk) 2014-09-10
NO2424569T3 (fr) 2018-03-17
JP2017039735A (ja) 2017-02-23
AU2010243942B2 (en) 2015-01-29
CN102458477B (zh) 2016-08-24
HRP20200884T1 (hr) 2020-09-04
EP3292874B1 (fr) 2020-04-08
CO6450601A2 (es) 2012-05-31
MX2011011365A (es) 2012-09-28
HUE037853T2 (hu) 2018-09-28
PE20120556A1 (es) 2012-05-09
PT3292874T (pt) 2020-05-15
UY32560A (es) 2010-11-30
US20120189644A1 (en) 2012-07-26
CA2760114A1 (fr) 2010-11-04
HN2011002834A (es) 2013-10-28
CY1119738T1 (el) 2018-06-27
LT2424569T (lt) 2018-02-12
PL2424569T3 (pl) 2018-03-30
US9084829B2 (en) 2015-07-21
SI2424569T1 (en) 2018-02-28
HK1170671A1 (zh) 2013-03-08
BRPI1014637A2 (pt) 2019-04-16
AU2010243942A8 (en) 2012-06-07
BRPI1014637B1 (pt) 2021-08-24

Similar Documents

Publication Publication Date Title
MA33229B1 (fr) Immunoconjugues anti-mesotheline et leurs utilisations
MA30634B1 (fr) Anticorps antagoniste pour le traitement du cancer
Sutherland et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
US20230270878A1 (en) Drug conjugates comprising antibodies against claudin 18.2
Iyer et al. Antibody drug conjugates—Trojan horses in the war on cancer
MA38194A1 (fr) Anticorps anti-ceacam5 et leurs utilisations
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
Huang et al. Anti‐tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate‐specific membrane antigen
WO2004018000A3 (fr) Compositions et methodes de traitement du cancer a l'aide d'immunoconjugues cytotoxiques d'anticorps du cd44 et d'agents chimiotherapeutiques
MA33276B1 (fr) Anticorps spécifiques à la cadhérine-17
DE602005016773D1 (de) Antikrebs-antikörper mit reduzierter komplementfixierung
MA31662B1 (fr) Anticorps chimeres et humanises anti-cd44 influencant la cytotoxicite des cellules cancereuses
MA30675B1 (fr) Granules de nitrate d'ammonium
Barreca et al. Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
Campos et al. The target invites a foe: antibody–drug conjugates in gynecologic oncology
MX2023008803A (es) Inmunoconjugados que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos.
MA34487B1 (fr) Compositions d'anticorps anti-vegfr-3.
MA32815B1 (fr) Composition pour cibler des cellules dendritiques
Guffroy et al. Improving the safety profile of ADCs
MA38848A1 (fr) Anticorps anti-prlr et utilisations associées
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation
Kim et al. Antibody-immunotoxin Conjugate Using FcBP-mediated Photoconjugation to Treat Cancer
US20230330258A1 (en) Conjugates comprising a phosphorus (v) and a drug moiety
Gava Contract
MA42523B1 (fr) Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations